COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

The purpose of this study is to find out whether an investigational product, called LN-145, is safe and effective in the treatment of patients with Non-Small-Cell Lung Cancer (NSCLC). LN-145 is created by modifying your own cells and delivering them back in an infusion. This study is being sponsored by Iovance Biotherapeutics.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

21-0457

ClinicalTrials.gov

NCT04614103

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.